Recurrence after Successful Treatment of Multidrug-Resistant Tuberculosis in Taiwan

Meng-Yu Chen¹, Yi-Chun Lo¹, Wan-Chin Chen¹, Kwei-Feng Wang², Pei-Chun Chan²,³,⁴*

¹ Office of Preventive Medicine, Centers for Disease Control, Taipei, Taiwan, ² Division of Chronic Infectious Diseases, Centers for Disease Control, Taipei, Taiwan, ³ Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, ⁴ Division of Pediatric Infectious Diseases, Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan

* pcanita.tw@cdc.gov.tw

Abstract

Recurrence after successful treatment for multidrug-resistant tuberculosis (MDR-TB) is challenging because of limited retreatment options. This study aimed to determine rates and predictors of MDR-TB recurrence after successful treatment in Taiwan. Recurrence rates were analyzed by time from treatment completion in 295 MDR-TB patients in a national cohort. Factors associated with MDR-TB recurrence were examined using a multivariate Cox regression analysis. Ten (3%) patients experienced MDR-TB recurrence during a median follow-up of 4.8 years. The overall recurrence rate was 0.6 cases per 1000 person-months. Cavitation on chest radiography was an independent predictor of recurrence (adjusted hazard ratio [aHR] = 6.3; 95% CI, 1.2–34). When the analysis was restricted to 215 patients (73%) tested for second-line drug susceptibility, cavitation (aHR = 10.2; 95% CI, 1.2–89) and resistance patterns of extensively drug-resistant TB (XDR-TB) or pre-XDR-TB (aHR = 7.3; 95% CI, 1.2–44) were associated with increased risk of MDR-TB recurrence. In Taiwan, MDR-TB patients with cavitary lesions and resistance patterns of XDR-TB or pre-XDR-TB are at the highest risk of recurrence. These have important implications for MDR-TB programs aiming to optimize post-treatment follow-up and early detection of recurrent MDR-TB.

Introduction

Multidrug-resistant tuberculosis (MDR-TB), defined as tuberculosis caused by a strain of Mycobacterium tuberculosis resistant to at least isoniazid and rifampin, remains a global concern. Over the past several years, a growing number of studies have shown that recurrence after successful treatment of MDR-TB was not uncommon [1–15] (S1 Appendix). Reported recurrence rates vary worldwide from 0% after 2 years of follow-up [5,13,15] to 8.5% after 8 years of follow-up [6]. Managing patients with MDR-TB recurrence represents a challenge for medical and public health professionals because of limited retreatment options and continuing threat to close contacts.

In Taiwan, a national program for MDR-TB organized according to the World Health Organization (WHO) guidelines [16,17], named Taiwan MDR-TB Consortium (TMTC), was
launched in May 2007 [18]. It was implemented under the Taiwan National Tuberculosis Pro-
gram and augmented the conventional model of directly observed treatment, short course-
plus (DOTS-Plus) for MDR-TB patients. Between 2007 and 2011, the number of incident
MDR-TB patients remained unchanged, accounting for 1% of TB patients and 6% of retreated
patients [18,19]. The rate of treatment success increased from 61% to 82% after the implemen-
tation of the TMTC [20]. The number of prevalent MDR-TB patients also decreased from 440
in May 2007 to 210 in April 2014 [19]. However, whether long-term outcomes for patients
enrolled in the TMTC are also favorable is unknown. Moreover, studies on the predictors of
MDR-TB recurrence are few and limited by lack of adjustment for potential confounders
[1,4,6–9]. Elements necessary for identifying recurrences such as at-risk populations and both
the frequency and duration of follow-up have not been determined. We aimed to use the
national surveillance data to estimate MDR-TB recurrence rates under the TMTC and to eval-
uate predictors of MDR-TB recurrence in Taiwan.

Methods

Study setting and procedures

Since 2007 the TMTC has provided medical care and operated DOTS-Plus project to MDR-TB
patients through five professional therapeutic teams around the country. Designated observers
and nurses employed by therapeutic teams delivered individualized second-line anti-TB drugs
to patients, with enablers and incentives to support facing lengthy treatment of MDR-TB. The
DOTS-Plus team staff reported adverse events or other medical conditions to the physician in
charge of patients to concur the frequent encountered side effects of treatment [18,20]. Pulmo-
nary MDR-TB patients with positive culture results who had not completed treatment by Janu-
ary 2007 were informed of the TMTC and given the option to participate. The enrolment rate
of MDR-TB patients in the TMTC was 90% while refusal and relocation abroad were the two
main reasons why patients did not receive care of the TMTC [18]. Baseline demographics, con-
comitant diseases such as diabetics and cancer, disease severity, drug resistance, treatment
course and outcomes of patients participating in the TMTC were recorded in the TMTC regis-
try. Although human immunodeficiency virus (HIV) prevalence in Taiwan is low (0.16% in
2011) [21] and HIV testing was not mandatory for MDR-TB patients, the TMTC was encour-
aged to perform testing for all enrolled patients since 2009.

Drug susceptibility testing (DST) was first done on culture-positive isolates at laboratories
of designated hospitals. Culture-positive isolates were then submitted to the Reference Labora-
tory of Mycobacteriology at Taiwan Centers for Disease Control (TCDC) for confirmation of
MDR-TB and DST to second-line drugs. The TCDC Reference Laboratory of Mycobacteriol-
ogy used the Middle-brook 7H11 agar proportion method to perform DST for all drugs,
including fluoroquinolones (ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin) and second-
line injectable drugs (kanamycin, amikacin, capreomycin) [22]. Early in the program not all
isolates were tested for second-line DST. In the latter stages, such testing was done in almost
all collected isolates [20]. Regimens were routinely adjusted according to results of in vitro sus-
cceptibility testing as WHO guidelines [16]. Since individualized instead of standardized regi-
men was applied, the treatment duration could be tailored by clinical response, mainly
decided by physicians in charge of the patient.

Treatment outcomes were documented based on WHO standard definitions [17]: cured
meant patients completed treatment according to program protocol and had at least five con-
secutive negative cultures from samples collected at least 30 days apart in the final 12 months
of treatment; completed meant patients completed treatment according to program protocol
but did not meet the definition for cured because of lack of bacteriological results (i.e. fewer
than five cultures performed in the final 12 months of treatment). Treatment success included both cured and treatment completed. As all the other pulmonary TB patients, physicians were recommended to provide post-treatment follow-up for MDR-TB patients (i.e. chest radiograph and sputum collection every 6 months for a year after completion of treatment and then yearly thereafter) [23]. No other routine monitoring after completion of treatment was recommended specifically for MDR-TB patients.

Study design and data collection
We performed a cohort study among all laboratory-confirmed MDR-TB patients who were registered at the TMTC from May 2007 to December 2010 and achieved treatment success. The primary outcome of this study was the occurrence of active MDR-TB during follow-up after treatment success, defined as MDR-TB recurrence. Episodes of recurrent MDR-TB were identified when patients had at least one positive sputum culture for MDR-TB (with DST confirmation) collected at least 3 months after the end of successful treatment. Patients with positive sputum culture within 3 months after the end of treatment were considered treatment incomplete and not classified as recurrent MDR-TB. Time to recurrence was defined as the time between the documented end date of the treatment for MDR-TB and the date of positive sputum samples collection for recurrent MDR-TB. The cohort was followed up from the end of treatment until disease recurrence, death, and emigration or until 20 September 2014, whichever came first. We used unique national identification number and linked to routinely collected National Tuberculosis Registry data to identify recurrent episodes. All other data were collected from the TMTC registry database.

Statistical analysis
We calculated the percentage of patients who had a recurrence of MDR-TB and the timing of recurrence. We evaluated predictor variables associated with time to recurrence. Categorical variables are reported as proportions, and the comparisons between groups were carried out by using the chi-square test or Fisher’s exact test. All statistical tests were 2-sided, no multiple comparison adjustment was made, and \( p < 0.05 \) was considered statistically significant. We used Kaplan-Meier estimates to construct a cumulative recurrence-free curve and Cox proportional hazard models to conduct univariate and multivariate analyses. We counted the duration of follow-up from the end of treatment to recurrence or to the end of observation. We developed a full model including all potential explanatory variables and used a forced entry method, in which all variables were entered in a single step to identify factors independently associated with recurrence.

Results of DST to second-line drugs (fluoroquinolones and second-line injectable drugs) were missing for 27% of cases; hence, this variable was not included in the full model of multivariate analysis. However, as drug resistance patterns have been previously linked to treatment outcomes of MDR-TB [24], we enrolled patients who had undergone second-line DSTs in a subgroup analysis to assess its impact on recurrence.

All the analyses were performed using the SPSS statistical package, version 20.0 (SPSS Inc., Chicago, IL, USA) and proportional hazards assumption test was completed by using the SAS, version 9.3 (SAS Institute Inc., Cary, NC, USA).

Ethics statement
The study was approved by TCDC. As it was deemed public health surveillance, it was exempted from ethics approval by the Institutional Review Board of TCDC.
Results

There were 375 MDR-TB patients registered at the TMTC between May 2007 and December 2010, of whom 295 achieved treatment success (249 were cured, and 46 completed treatment) (Fig 1). These 295 patients with successful outcomes comprised our cohort of analysis. The characteristics of the 295 patients were summarized in Table 1. Among these 295 patients, 228 (77%) were male. The median age at the initiation of MDR-TB treatment was 48 years (inter-quartile range [IQR], 37–59 years). Of the 191 patients who underwent HIV testing, four (2.1%) were HIV positive. Patient classification in the registry showed that 62% had history of previous anti-TB treatment (relapse, treated after loss to follow-up, or treated after failure). Patients with previous treatment history were more likely to have cavitation on the chest radiograph compared to newly diagnosed patients (p = 0.005).

A total of 124 patients had resistance to streptomycin, representing 43% of those tested. Two hundred and fifteen patients had results of second-line DST available. Of these, 15 patients (7%) had strains of extensively drug-resistant tuberculosis (XDR-TB; MDR plus resistance to fluoroquinolone and second-line injectable drugs); 43 (20%) had strains of pre-extensively drug-resistant tuberculosis (pre-XDR-TB; MDR plus resistance to fluoroquinolone or second-line injectable drugs) (Table 1).

Among the 295 patients included, all received regimens with a fluoroquinolone and 283 (96%) received an injectable drug during the entire course of treatment. Treatment duration over 24 months was documented in 108 (37%) patients, which was more common in patients without inclusion of an injectable drug in the initial MDR-TB regimens (34/63) than among patients with injectable drugs included at treatment initiation (74/232) (p = 0.001).

Recurrence of MDR-TB

The median duration of post-treatment follow-up was 4.8 years (IQR, 4.1–5.3 years). By the end of the observation period, 10 (3.4%) patients had MDR-TB recurrence. Four of 10 recurrences occurred in the first year, two in the second year, and the other four occurred more than 2 years after treatment success (Fig 2). The incidence rate of recurrence was 1.2 cases per 1000 person-months (95% confidence interval [CI], 0.5–3.0 cases per 1000 person-months) in the first 12 months after treatment success and 0.6 cases per 1000 person-months (95% CI, 0.2–2.2 cases per person-months) in months 13–24 after treatment success. The overall incidence rate of recurrence was 0.6 cases per 1000 person-months (95% CI, 0.4–1.2 cases per 1000 person-months). The demographics, drug resistance patterns and treatment courses of the 10 patients experiencing recurrence were summarized in Table 2. Results of second-line DST in original and recurrent strains were both known for 6 patients (3 MDR-TB, 2 pre-XDR-TB and 1 XDR-TB) (Table 2 and S2 Table). None of them acquired additional resistance to fluoroquinolones or second-line injectable drugs between two episodes of MDR-TB. By the end of observation, six patients had achieved treatment success for recurrent episodes, two were still under treatment, one patient had died, and one had failed. The patient who failed treatment is currently categorized as a chronic case, attributed to poor response due to interactions between anti-psychotic medications and second-line anti-TB drugs.

In univariate analysis, patients who had cavitation on chest radiography at the time of diagnosis had a 5-fold increase in the risk of MDR-TB recurrence (hazard ratio [HR], 5.5 [95% CI, 1.2–26]; p = 0.03; Table 1). Treatment duration more than 24 months was not associated with recurrence (HR, 3.6 [95% CI, 0.9–14], p = 0.07). In multivariate analysis with covariates adjusted for disease severity and treatment outcomes (proportional hazards assumption test, p = 0.597), cavitation on chest radiography remained independently associated with an increased risk of MDR-TB recurrence (adjusted hazard ratio [aHR], 6.3 [95% CI, 1.2–34]; p = 0.03; S1 Table).
Subgroup analysis

In our cohort, 215 patients (73%) had results for second-line DST and 80 (27%) did not. Availability of results of second-line DST was associated with sputum smear positivity ($p = 0.03$) and inversely proportional to culture conversion before the use of second-line drugs ($p < 0.001$) (Table 3). Otherwise, no significant difference was observed between patients with
Table 1. Baseline characteristics of multidrug-resistant tuberculosis patients with treatment success (n = 295).

| Characteristic                              | Patients n | MDR-TB recurrence n (%) | Univariate HR (95% CI) | P value |
|---------------------------------------------|------------|-------------------------|------------------------|---------|
| **Total**                                   | 295        | 10 (3)                  |                        |         |
| **Gender**                                  |            |                         |                        |         |
| Male                                        | 228        | 9 (4)                   | 2.8 (0.3–22)           | 0.33    |
| Female                                      | 67         | 1 (1)                   | Reference              |         |
| **Age groups (years)**                      |            |                         |                        |         |
| >60                                         | 66         | 2 (3)                   | 0.6 (0.1–3.1)          | 0.52    |
| 35–60                                       | 163        | 4 (3)                   | 0.4 (0.1–1.7)          | 0.23    |
| <35                                         | 66         | 4 (6)                   | Reference              |         |
| **Aboriginal**                              |            |                         |                        |         |
| Yes                                         | 61         | 0 (0)                   | —                      | —       |
| No                                          | 234        | 10 (4)                  |                        |         |
| **BMI (kg/m²)**                             |            |                         |                        |         |
| <18.5                                       | 56         | 1 (2)                   | 0.9 (0.1–13)           | 0.91    |
| 18.5–25                                     | 195        | 8 (4)                   | 1.9 (0.2–15)           | 0.56    |
| ≥25                                         | 44         | 1 (2)                   | Reference              |         |
| **Diabetes mellitus**                       |            |                         |                        |         |
| Yes                                         | 92         | 5 (5)                   | 2.2 (0.6–7.6)          | 0.21    |
| No                                          | 203        | 5 (3)                   | Reference              |         |
| **Hypertension**                            |            |                         |                        |         |
| Yes                                         | 51         | 1 (2)                   | 0.6 (0.1–4.2)          | 0.55    |
| No                                          | 244        | 9 (4)                   | Reference              |         |
| **Hepatitis B**                             |            |                         |                        |         |
| Yes                                         | 23         | 0 (0)                   | —                      | —       |
| No                                          | 272        | 10 (4)                  |                        |         |
| **Hepatitis C**                             |            |                         |                        |         |
| Yes                                         | 25         | 1 (4)                   | 1.3 (0.2–10)           | 0.82    |
| No                                          | 270        | 9 (3)                   | Reference              |         |
| **HIV infected (n = 191)**                  |            |                         |                        |         |
| Yes                                         | 4          | 0 (0)                   | —                      | —       |
| No                                          | 187        | 7 (4)                   |                        |         |
| **Patient classification**                  |            |                         |                        |         |
| Treatment after failure of previous treatment| 75         | 2 (3)                   | 1.5 (0.2–10)           | 0.70    |
| Treatment after loss to follow-up           | 17         | 1 (6)                   | 3.5 (0.3–39)           | 0.30    |
| Relapse                                     | 92         | 5 (6)                   | 3.1 (0.6–16)           | 0.18    |
| New                                         | 111        | 2 (2)                   | Reference              |         |
| **Cavitation on initial CXR**               |            |                         |                        |         |
| Yes                                         | 124        | 8 (7)                   | 5.5 (1.2–26)           | 0.03    |
| No                                          | 171        | 2 (1)                   | Reference              |         |
| **Sputum smear positivity at time of diagnosis** |          |                         |                        |         |
| Yes                                         | 174        | 6 (3)                   | 1.0 (0.3–3.7)          | 0.96    |
| No                                          | 121        | 4 (3)                   | Reference              |         |
| **Second-line DST (n = 215)**               |            |                         |                        |         |
| XDR                                         | 15         | 1 (7)                   | 2.6 (0.3–23)           | 0.39    |
| Pre-XDR                                     | 43         | 3 (7)                   | 2.7 (0.6–12)           | 0.19    |
| MDR only                                    | 157        | 4 (3)                   | Reference              |         |
| **Treatment delay**                         |            |                         |                        |         |
| Yes                                         | 77         | 4 (5)                   | 1.9 (0.5–6.6)          | 0.34    |

(Continued)
### Table 1. (Continued)

| Patients n | MDR-TB recurrence n (%) | Univariate HR (95% CI) | P value |
|------------|-------------------------|------------------------|---------|
| No 218     | 6 (3)                   | Reference              |         |
| Culture conversion before initiating SLD | | | |
| Yes 73     | 3 (4)                   | 1.3 (0.3–4.9)          | 0.73    |
| No 222     | 7 (3)                   | Reference              |         |
| Time from initiating SLD to culture conversion | | | |
| ≥2 months 117 | 3 (3)                   | 0.6 (0.2–2.5)          | 0.52    |
| <2 months 178 | 7 (4)                   | Reference              |         |
| Treatment outcome | | | |
| Completed 46 | 3 (7)                   | 2.4 (0.6–9.2)          | 0.21    |
| Cured 249 | 7 (3)                   | Reference              |         |

BMI, body mass index; CI, confidence interval; CXR, chest radiography; DST, drug susceptibility test; HR, hazard ratio; MDR-TB, multidrug-resistant tuberculosis (resistance to at least isoniazid and rifampin); MDR only, MDR-TB but susceptible fluoroquinolones and second-line injectable drugs; pre-XDR, MDR-TB plus resistance to any fluoroquinolone or any second-line injectable drug; SLD, second-line drugs (include fluoroquinolones and second-line injectable drugs); XDR, extensively drug-resistant tuberculosis (MDR-TB plus resistance to any fluoroquinolone and any second-line injectable drug).

*The lag between sputum collection of MDR-TB and start of second-line drugs >120 days.

doi:10.1371/journal.pone.0170980.t001

![Figure 2](https://example.com/f2.png) Recurrence free survival curve for multidrug-resistant tuberculosis patients (n = 295).

doi:10.1371/journal.pone.0170980.g002
Table 2. Characteristics and treatment outcomes of 10 patients with multidrug-resistant tuberculosis recurrence.

| Case No. | Gender | Age (y) | Status at time of initiating treatment (patient classification) | Sputum smear at time of diagnosis | Cavitation on CXR | Second-line DST \(^a\) | Time to conversion (m)\(^b\) | Treatment outcome | Treatment duration (m) | Interval to recur (m) | Sputum smear at time of diagnosis | Cavitation on CXR | Second-line DST \(^a\) | Treatment outcome |
|----------|--------|---------|---------------------------------------------------------------|----------------------------------|-------------------|------------------------|--------------------------|-------------------|------------------------|------------------------|----------------------------------|-------------------|------------------------|-------------------|
| 1        | M      | 18      | New                                                          | Negative                         | Yes                | NA                     | 1.8                      | Cure              | 21.3                   | 8.0                    | Negative                        | No                | Pre-XDR                 | Complete          |
| 2        | M      | 61      | New                                                          | Negative                         | No                 | Pre-XDR                | 1.3                      | Cure              | 33.8                   | 9.8                    | Negative                        | No                | NA                      | Death             |
| 3        | M      | 24      | Relapse                                                      | Positive                         | Yes                | MDR only               | 19.6                     | Complete          | 29.4                   | 32.0                   | Positive                        | Yes               | MDR only                | Cure              |
| 4        | M      | 35      | Relapse                                                      | Negative                         | No                 | MDR only               | 0.3                      | Complete          | 20.3                   | 23.8                   | Negative                        | No                | MDR only                | Cure              |
| 5        | M      | 41      | Relapse                                                      | Positive                         | Yes                | Pre-XDR                | 19.3                     | Cure              | 41.9                   | 3.3                    | Positive                        | Yes               | XDR                     | Cure              |
| 6        | F      | 49      | Relapse                                                      | Positive                         | Yes                | XDR                    | 1.3                      | Cure              | 40.6                   | 6.7                    | Positive                        | Yes               | XDR                     | Chronic           |
| 7        | M      | 61      | Relapse                                                      | Positive                         | Yes                | MDR only               | 1.7                      | Complete          | 25.1                   | 27.1                   | Positive                        | Yes               | MDR only                | Under treatment |
| 8        | M      | 46      | Return from loss to follow-up                                | Positive                         | Yes                | MDR only               | 0.3                      | Cure              | 29.2                   | 23.2                   | Positive                        | Yes               | NA                      | Cure              |
| 9        | M      | 47      | After failure                                                | Positive                         | Yes                | MDR only               | 4.2                      | Cure              | 35.4                   | 51.1                   | Positive                        | No                | Pre-XDR                 | Under treatment |
| 10       | M      | 53      | After failure                                                | Positive                         | Yes                | Pre-XDR                | 19.6                     | Cure              | 41.9                   | 3.3                    | Positive                        | Yes               | XDR                     | Chronic           |

CXR, chest radiography; DST: drug susceptibility test; NA, not available; MDR-TB, multidrug-resistant tuberculosis (resistance to at least isoniazid and rifampin); MDR only, MDR-TB, but susceptible to fluoroquinolones and second-line injectable drugs; pre-XDR, MDR-TB plus resistance to any fluoroquinolone or any second-line injectable drug; XDR, extensively drug-resistant tuberculosis (MDR-TB plus resistance to any fluoroquinolone and any second-line injectable drug).

\(^a\) See the full susceptibility results on S2 Table.
\(^b\) Time from initiating second-line drugs (fluoroquinolones and second-line injectable drugs) to culture conversion.
\(^c\) Case 5 had conversion before receiving second-line drugs.

doi:10.1371/journal.pone.0170980.t002
and without results of second-line DST. Among the 215 patients with second-line DST results, 8 patients had MDR-TB recurrence. In multivariate analysis (proportional hazards assumption test, $p = 0.602$), drug resistance patterns of XDR-TB or pre-XDR-TB were independently associated with an increased risk of recurrence (HR, 7.3 [95% CI, 1.2–44]; $p = 0.03$). Cavitation on chest radiography was still significantly associated with an increased risk of recurrence (HR, 10.2 [95% CI, 1.2–89]; $p = 0.04$) (S1 Table).

**Discussion**

In this nationwide study with a median duration of follow-up of 4.8 years, 10 (3.4%) of the 295 MDR-TB patients experienced MDR-TB recurrence. Incidences of recurrence in the first 12
months and between months 13–24 of follow-up were lower than or comparable to those reported from the MDR-TB program in Peru [1,2] and Russia [7]. Such low rates of recurrence—either in terms of recurrence proportion or incidence rate—demonstrate the effectiveness of our MDR-TB program, characterized by government-organized, hospital-initiated, and patient-centered care [20].

The low recurrence rate in our study can be explained by at least two reasons. First, MDR-TB patients in our cohort were managed by a consortium of specialized treatment facilities where better adherence and more aggressive follow-up after treatment were more likely to achieve compared to care under traditional community service. The effective drug administration may therefore lead to a more favorable treatment outcome and lower risk for recurrence. Second, the variation of case definitions and follow-up periods in different MDR-TB programs may affect the estimates of recurrence rates. It should be noted that in this study we included only patients with full culture confirmation of MDR-TB as recurrence while in previous studies case definition may include some patients who had re-initiation of treatment but no culture confirmation or DST available for the isolates from recurrent episodes [1,3,7]. Our strict case definition may not be the most sensitive definition but more accurately reflect the true burden of recurrence diseases. Moreover, we found DST results for fluoroquinolones and second-line injectable drugs did not differ between the cultures from two episodes, implying that the observed recurrence rate in this study can be regarded as an estimate of the relapse rate, an important measure of treatment efficacy. Although it would be preferable to use molecular genotyping to differentiate true relapse from reinfection [7,25] such analyses are rarely performed extensively under programmatic conditions [26].

The recommendation of frequency and duration for follow-up of MDR-TB patients has not been well established. Most MDR-TB programs conducted regular follow-up within 2 years after treatment completion for MDR-TB [3,10,13–15]. The study in Peru suggested follow-up for a second year might not be warranted [2] while the teams from Estonia and Russia recommended prolonged follow-up be needed for early detection and treatment of recurrence [6,7]. The recurrence rate in our study peaked during the first year of follow-up, supporting Gelmanova and colleagues’ assumption that MDR-TB relapse typically occurs soon after completion of treatment [7]. Moreover, a number of recurrences in our study occurred beyond the second year of follow-up. This implies the prolonged risk of recurrence in MDR-TB patients even when treatment success has been achieved. We therefore recommend post-treatment follow-up for more than 2 years for MDR-TB patients as TBNet consensus [27]. Patients should also be informed of the long-term risk and of the signs and symptoms of recurrence, especially if MDR-TB programs cannot provide long-term, active follow-up.

It would be more feasible to have predictors for MDR-TB recurrence to identify susceptible patients and minimize the resource burden of post-treatment follow-up. We found that cavitation on chest radiography at the start of treatment was important in predicting MDR-TB recurrence. The occurrence of cavitary lesions in MDR-TB patients ranged widely in previous studies (from 24% to 69%) [1,4,6,12–14]. In our cohort 42% had chest cavitation, possibly attributable to the fact that 62% of our patients had previously received treatment. Chest radiographic findings are linked to severity of TB, and the association between cavitary disease and delay in diagnosis is well documented [28]. The presence of cavities has also been considered as an important risk factor for recurrent tuberculosis [29]. Probable explanations for this association include poor penetration by anti-TB drugs into the cavity [29,30], high bacilli load or sub-optimum dosing in patients with cavitation leading to reduced drug effectiveness [31], and increased propensity of mycobacteria to infect previously damaged lung tissue [29,32]. Genetic components to the host immune response to MDR-TB may also predispose some patients to disease recurrence [31]. We therefore propose MDR-TB patients with cavitation be prioritized...
for post-treatment follow-up to detect recurrence timely. Alternatively, advanced TB diseases like cavitation can be prevented through early case-finding, early diagnosis and a prompt start to effective treatment [17,31]. Whether prolonged treatment courses or aggressive regimens [1] provide benefit in reducing recurrence in patients with cavitation requires further evaluation.

We also found that pre-XDR-TB or XDR-TB patients were more likely to experience disease recurrence, suggesting that treatment regimens for patients with higher levels of drug resistance were inadequate. The findings are consistent with those of our earlier study [20], showing that resistance to quinolones or XDR-TB was associated with lower probability of treatment success. Pre-XDR-TB and XDR-TB are known to be risk factors for poor treatment outcomes [33–35]. Many clinical and programmatic factors may contribute to suboptimal treatment in patients with extensive drug resistance: limited effective drug options, shortened treatment duration due to adverse effects of toxic second-line antibiotics, delays in second-line DST, and lack of supply of later-generation or new anti-TB drugs [1,36]. With development of new MDR-TB medications such as Bedaquiline and Delamanid [37], lower toxicity and higher adherence to treatment are anticipated compared to pre-existing second-line medications. Interventions to minimize exposure to ineffective treatment, careful management of adverse events during treatment, and rapid DST are crucial to reduce recurrence in these difficult-to-treat groups.

Our study has several limitations. First, although MDR-TB recurrence in our study was confirmed by culture and DST, molecular genotyping was not performed in all the recurrent paired strains, which may have resulted in overestimation of recurrence through inadvertent inclusion of reinfection with new MDR-TB strains [25,38]. However, there is little chance of reinfection because the prevalence of MDR-TB was low and declining during the follow-up period of this cohort. Moreover, from our ongoing research of molecular genotyping (data not reported) we found that the strains of two episodes of MDR-TB were identical in eight patients (the strains in the other two patients were not available). Therefore the recurrences in our patients were more likely to attribute to relapse and the recurrence reported in this study was close to the true relapse rate. Second, it is likely that not all patients with recurrence were identified because clinical follow-up after treatment completion is not mandatory in our program. Therefore, the actual number of patients with recurrence may be underestimated. However, we linked data from the National TB registry to identify any new notification after the end of treatment, where notifications have been reinforced by the government policy of ‘no-notification-no-reimbursement’ since 1997 [39]. Thus, the probability of patients with recurrence not identified by our surveillance systems should be low. Third, the relatively small number of recurrences, however, reduced the power of the analysis to detect predictors or significant interactions. Finally, because MDR-TB patients in this cohort were older (with median age 48 years) and less co-infected with HIV (2%), our findings may not be applicable to other MDR-TB programs in which patients are young and facing high HIV burden.

In conclusion, our study showed that most MDR-TB patients remained recurrence-free for 5 years after treatment success under the TMTC. Our analysis found specific predictors of recurrence including cavitation on the initial chest radiograph and resistance patterns of XDR-TB or pre-XDR-TB. Active follow-up of MDR-TB patients for more than 2 years after treatment completion is a reasonable way to detect late recurrence, but the optimal frequency and content of follow-up require further investigation.

Supporting Information

S1 Appendix. Methods and results of literature review of multidrug-resistant tuberculosis recurrence.

(DOCX)
S1 Table. Multivariate analyses of potential predictors of multidrug-resistant tuberculosis recurrence (n = 295).

S2 Table. Detailed information of drug susceptibility results in 10 patients with multidrug-resistant tuberculosis recurrence.

Acknowledgments

We thank the staff in each of the hospitals in Taiwan Multidrug-resistant Tuberculosis Consortium who facilitate the operation of this program. We would like to acknowledge Jiunn-Ru Lin and Jing-Han Liu for data capture and management. We are also grateful for the Reference Laboratory of Mycobacteriology, the Centers for Disease Control, Taiwan, where the confirmation testing of MDR-TB and drug susceptibility tests were performed. We thank Geoff Hughes for English language support.

Author Contributions

Conceptualization: MYC WCC KFW PCC.
Data curation: MYC PCC.
Formal analysis: MYC PCC.
Investigation: KFW PCC.
Methodology: MYC PCC.
Project administration: KFW PCC.
Supervision: KFW PCC.
Validation: MYC YCL WCC PCC.
Visualization: MYC.
Writing – original draft: MYC PCC.
Writing – review & editing: MYC YCL WCC PCC.

References

1. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis 2013; 56: 770–776. doi: 10.1093/cid/cis1008 PMID: 23223591
2. Becerra MC, Appleton SC, Franke MF, Chalco K, Bayona J, Murray MB, et al. Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. Clin Infect Dis 2010; 51: 709–711. doi: 10.1086/655892 PMID: 20687835
3. Kwak N, Kim HR, Yoo CG, Kim YW, Han SK, Yim JJ. Changes in treatment outcomes of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2015; 19: 525–530. doi: 10.5588/ijtld.14.0739 PMID: 25868019
4. Lee J, Lim HJ, Cho YJ, Park YS, Lee SM, Yang SC, et al. Recurrence after successful treatment among patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2011; 15: 1331–1333. doi: 10.5588/ijtld.11.0098 PMID: 22283890
5. Karagoz T, Yazicioglu Mocin O, Pazari T, Senol T, Yetis Duman D, Duman G, et al. The treatment results of patients with multidrug resistant tuberculosis and factors affecting treatment outcome. Tuberk Toraks 2009; 57: 383–392. PMID: 20037853
6. Blondal K, Viiklepp P, Guethmundsson LJ, Altavra A. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 1228–1233. doi: 10.5588/ijtld.12.0037 PMID: 22748131

7. Gelmanova IY, Ahmad Khan F, Becerra MC, Zemlyanova NA, Unakova IA, Andreev YG, et al. Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia. Int J Tuberc Lung Dis 2015; 19: 399–405. doi: 10.5588/ijtld.14.0415 PMID: 25859994

8. Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006; 28: 980–985. doi: 10.1183/09031936.06.00125705 PMID: 16837502

9. Leung EC, Yew WW, Leung CC, Leung WM, Tam CM. Shorter treatment duration for selected patients with multidrug-resistant tuberculosis. Eur Respir J 2011; 38: 227–230. doi: 10.1183/09031936.00186310 PMID: 21719503

10. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180–1187. doi: 10.5588/ijtld.13.0100 PMID: 25216831

11. Anderson LF, Tamme S, Watson JP, Cohen T, Mitnick C, Brown T, et al. Treatment outcome of multidrug-resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill 2013; 18.

12. Yoshiyama T, Morimoto K, Okumura M, Sasaki Y, Ogata H, Shiraishi Y, et al. Long term outcome of multidrug-resistant TB patients in Fukujuji Hospital in Japan. Trans R Soc Trop Med Hyg 2014; 108: 589–590. doi: 10.1093/trstmh/tru080 PMID: 24902580

13. Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188–1194. doi: 10.5588/ijtld.13.0075 PMID: 25216832

14. Burgos M, Gonzalez LC, Paz EA, Gournis E, Kawamura LM, Schecter G, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40: 968–975. doi: 10.1086/428582 PMID: 15824988

15. Kuaban C, Noeske J, Rieder HL, Ait-Khaled N, Abena Foe JL, Trebucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517–524. doi: 10.5588/ijtld.14.0535 PMID: 25868018

16. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO; 2006.

17. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: WHO; 2008.

18. Huang SH, Wang KF, Chan PC, Yang CH, Chen CH. Evolution of MDR-TB control strategy in Taiwan. Taiwan Epidemiol Bull 2012; 28: 269–278.

19. Taiwan Centers for Disease Control. Taiwan Tuberculosis Control Report 2013. Taipei: Taiwan Centers for Disease Control; 2014.

20. Chan PC, Huang SH, Yu MC, Lee SW, Huang YW, Chien ST, et al. Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients—a retrospective cohort study. PLoS One 2013; 8: e57719. doi: 10.1371/journal.pone.0057719 PMID: 23451263

21. Yang CH, Chen KJ, Tsai JJ, Lin YH, Cheng SW, Wang KF, et al. The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study. BMC Infect Dis 2014; 14: 304–304. doi: 10.1186/1471-2334-14-304 PMID: 24897928

22. Wu MH, Jou R. Feasibility of multidrug-resistant tuberculosis treatment with improved regimens based on drug resistance profiles. 46th Union World Conference on Lung Health. Cape Town, South Africa: International Union Against Tuberculosis and Lung Disease; 2015:S505.

23. Taiwan Centers for Disease Control. Taiwan Guidelines for TB Diagnosis and Treatment, 5th edition. Taipei: Taiwan Centers for Disease Control; 2013.

24. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914. doi: 10.1371/journal.pone.0006914 PMID: 19742330

25. Yim JJ, Koh WJ. MDR-TB recurrence after successful treatment: additional studies using molecular genotyping are needed. Int J Tuberc Lung Dis 2015; 19: 371. doi: 10.5588/ijtld.15.0117 PMID: 25859987

26. Guerra-Assuncao JA, Houben RM, Crampin AC, Mzembe T, Mallard K, Coll F, et al. Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up. J Infect Dis 2015; 211: 1154–1163. doi: 10.1093/infdis/jiu574 PMID: 25336729
27. Lange C, Abubakar I, Alffenaa JW, Bothamley G, Caminero JA, Carvalho AC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23–63. doi: 10.1183/09031936.00188313 PMID: 24659544

28. Golub JE, Bur S, Cronin WA, Gange S, Baruch N, Comstock GW, et al. Delayed tuberculosis diagnosis and tuberculosis transmission. Int J Tuberc Lung Dis 2006; 10: 24–30. PMID: 16466033

29. Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007; 11: 828–837. PMID: 17705947

30. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360: 528–534. PMID: 12241657

31. World Health Organization. Toman’s tuberculosis: case detection, treatment and monitoring-questions and answers. Geneva: WHO; 2004.

32. Corbett EL, Churchyard GJ, Clayton T, Herselman P, Williams B, Hayes R, et al. Risk factors for pulmonary mycobacterial disease in South African gold miners. A case-control study. Am J Respir Crit Care Med 1999; 159: 94–99. doi: 10.1164/AJCCM.159.1.9803048 PMID: 9872824

33. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 113–119. doi: 10.1164/ajccm.200911-1656OC PMID: 20224066

34. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6–14. doi: 10.1086/653115 PMID: 20504231

35. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156–168. doi: 10.1183/09031936.00134712 PMID: 23100499

36. Caminero JA, Matteelli A, Loddenkemper R. Tuberculosis: are we making it incurable? Eur Respir J 2013; 42: 5–8. doi: 10.1183/09031936.00206712 PMID: 23813308

37. Brigden G, Hewison C, Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect Drug Resist 2015; 8: 367–378. doi: 10.2147/IDR.S68351 PMID: 26586956

38. Lambert ML, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or re infection? Lancet Infect Dis 2003; 3: 282–287. PMID: 12726976

39. Chiang CY, Enarson DA, Yang SL, Suo J, Lin TP. The impact of national health insurance on the notification of tuberculosis in Taiwan. Int J Tuberc Lung Dis 2002; 6: 974–979. PMID: 12475143